PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease
    Stein, Evan A.
    Raal, Frederick
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (01) : 101 - 108
  • [42] Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
    Arca, Marcello
    ATHEROSCLEROSIS, 2017, 256 : 134 - 145
  • [43] Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience
    Alonso, Rodrigo
    Muniz-Grijalvo, Ovidio
    Luis Diaz-Diaz, Jose
    Zambon, Daniel
    de Andres, Raimundo
    Arroyo-Olivares, Raquel
    Fuentes-Jimenez, Francisco
    Sanchez Munoz-Torrero, Juan
    Cepeda, Jose
    Aguado, Rocio
    Alvarez-Banos, Pilar
    Casanas, Marta
    Dieguez, Marta
    Dolores Manas, Maria
    Rubio, Patricia
    Argueso, Rosa
    Arrieta, Francisco
    Gonzalez-Bustos, Pablo
    Perez-Isla, Leopoldo
    Mata, Pedro
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (04) : 584 - 592
  • [44] Conceptual design of hybrid PCSK9 lead inhibitors against coronary artery disease
    Puratchikody, Ayarivan
    Irfan, Navabshan
    Balasubramaniyan, Sakthivel
    BIOCATALYSIS AND AGRICULTURAL BIOTECHNOLOGY, 2019, 17 : 427 - 440
  • [45] Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units
    Scicali, Roberto
    Mandraf, Giuseppe
    Di Pino, Antonino
    Scuruchi, Michele
    Ferrara, Viviana
    Squadrito, Giovanni
    Purrello, Francesco
    Piro, Salvatore
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (12) : 3401 - 3406
  • [46] PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
    Wang, Xing
    Wen, Dingke
    Chen, Yuqi
    Ma, Lu
    You, Chao
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [47] Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review
    Shahid, Rabia
    Naik, Shaili S.
    Ramphall, Shivana
    Rijal, Swarnima
    Prakash, Vishakh
    Ekladios, Heba
    Saju, Jiya Mulayamkuzhiyil
    Mandal, Naishal
    Kham, Nang I.
    Hamid, Pousette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [48] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
    Wu, M. F.
    Xu, K. Z.
    Guo, Y. G.
    Yu, J.
    Wu, Y.
    Lin, L. M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (06) : 739 - 748
  • [49] PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives
    Gupta, Jitendra
    Gupta, Reena
    CURRENT MOLECULAR PHARMACOLOGY, 2023, 16 (08) : 832 - 854
  • [50] The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
    Imbalzano, Egidio
    Ilardi, Federica
    Orlando, Luana
    Pintaudi, Basilio
    Savarese, Gianluigi
    Rosano, Giuseppe
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 318 - 327
12345